Discover
NGNE
Neurogene Inc.
33.88
2 x 23.89
2 x 40.42
bid
ask
+
2.43
7.73%
2 @ 05:24 AM
34.17 +0.29 (0.86%)
| Ytd | 64.47% | |
| 1y | 76.55% |
31.43
day range
34.35
15.93
52 week range
37.27
| Open | 31.89 | Prev Close | 31.45 | Low | 31.43 | High | 34.35 | Mkt Cap | 535.37M |
| Vol | 677.22K | Avg Vol | 180.08K | EPS | -4.55 | P/E | N/A | Forward P/E | -4.85 |
| Beta | N/A | Short Ratio | 7.15 | Inst. Own | 110.72% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-11 | 50-d Avg | 28.97 | 200-d Avg | 23.63 | 1yr Est | 52.80 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-18 | 2024-09 | -1.23 | -1.19 | 0.04 | 3.25% |
| 2024-08-09 | 2024-06 | -1.02 | -1.09 | -0.07 | -6.86% |
| 2024-05-10 | 2024-03 | -1.03 | -1 | 0.03 | 2.91% |
| 2024-04-02 | 2023-12 | -1.3 | N/A | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-11-25 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-11-20 | BMO Capital | Upgrade | Outperform | Outperform |
| 2024-11-19 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-11-12 | Stifel | Upgrade | Buy | Buy |
| 2024-11-12 | BMO Capital | Upgrade | Outperform | Outperform |
| 2024-11-12 | Leerink Partners | Upgrade | Outperform | Outperform |
Profile
Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2023-10-04 | BAKER BROS ADVISORS L.P. | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Conversion of Exercise of derivative security |
| 2024-03-12 | COBB STUART | Officer | 20.39K | Stock Award(Grant) |
| 2024-11-21 | CVIJIC CHRISTINE MIKAIL | President | 76.84K | Purchase |
| 2024-11-21 | MCMINN RACHEL L. PH.D. | Chief Executive Officer | 1.30M | Purchase |
| 2023-04-02 | PATEL PRITI | Former | 37.31K | Sale |
| 2024-11-25 | SAMSARA BIOCAPITAL GP, LLC | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Purchase |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Blackrock Inc. | 1.37M | 30.87M | 9.24% |
| 2024-09-29 | EcoR1 Capital, LLC | 1.27M | 28.61M | 8.56% |
| 2024-09-29 | Samsara BioCapital, LLC | 1.27M | 28.53M | 8.53% |
| 2024-09-29 | RTW Investments LP | 1.14M | 25.54M | 7.64% |
| 2024-09-29 | Great Point Partners LLC | 1.00M | 22.60M | 6.76% |
| 2024-09-29 | Redmile Group, LLC | 964.35K | 21.70M | 6.49% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 335.98K | 7.56M | 2.26% |
| 2024-09-29 | BlackRock Health Sciences Term Trust | 326.88K | 7.35M | 2.20% |
| 2024-08-30 | Fidelity Small Cap Growth Fund | 288.92K | 6.50M | 1.94% |
| 2024-08-30 | Blackrock Funds-Health Sciences Opportunity Portfolio | 284.04K | 6.39M | 1.91% |
| 2024-09-29 | Janus Henderson Global Life Sciences Fund | 278.17K | 6.26M | 1.87% |
| 2024-10-30 | iShares Russell 2000 ETF | 265.76K | 5.98M | 1.79% |